IL138949A0 - 4-benzyl piperidine alkylsulfoxide heterocycles and use as subtype-selective nmda receptor antagonists - Google Patents

4-benzyl piperidine alkylsulfoxide heterocycles and use as subtype-selective nmda receptor antagonists

Info

Publication number
IL138949A0
IL138949A0 IL13894999A IL13894999A IL138949A0 IL 138949 A0 IL138949 A0 IL 138949A0 IL 13894999 A IL13894999 A IL 13894999A IL 13894999 A IL13894999 A IL 13894999A IL 138949 A0 IL138949 A0 IL 138949A0
Authority
IL
Israel
Prior art keywords
subtype
receptor antagonists
nmda receptor
selective nmda
benzyl piperidine
Prior art date
Application number
IL13894999A
Other languages
English (en)
Original Assignee
Warner Lambert Company Cocensy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Company Cocensy filed Critical Warner Lambert Company Cocensy
Publication of IL138949A0 publication Critical patent/IL138949A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13894999A 1998-06-26 1999-06-25 4-benzyl piperidine alkylsulfoxide heterocycles and use as subtype-selective nmda receptor antagonists IL138949A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9091498P 1998-06-26 1998-06-26
PCT/US1999/014291 WO2000000197A1 (fr) 1998-06-26 1999-06-25 Heterocycles de 4-benzyl-piperidine alkylsulfoxyde et leur utilisation comme antagonistes selectifs de sous-type du recepteur du nmda

Publications (1)

Publication Number Publication Date
IL138949A0 true IL138949A0 (en) 2001-11-25

Family

ID=22224939

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13894999A IL138949A0 (en) 1998-06-26 1999-06-25 4-benzyl piperidine alkylsulfoxide heterocycles and use as subtype-selective nmda receptor antagonists

Country Status (28)

Country Link
US (1) US6284774B1 (fr)
EP (1) EP1089735B1 (fr)
JP (1) JP2002519322A (fr)
KR (1) KR20010053170A (fr)
CN (1) CN1304307A (fr)
AP (1) AP2000001949A0 (fr)
AT (1) ATE297207T1 (fr)
AU (1) AU769650B2 (fr)
BG (1) BG105082A (fr)
BR (1) BR9911575A (fr)
CA (1) CA2327888A1 (fr)
DE (1) DE69925730T2 (fr)
EA (1) EA200100058A1 (fr)
EE (1) EE200000778A (fr)
ES (1) ES2244201T3 (fr)
HU (1) HUP0102471A2 (fr)
ID (1) ID28005A (fr)
IL (1) IL138949A0 (fr)
IS (1) IS5667A (fr)
NO (1) NO20006482L (fr)
NZ (1) NZ508808A (fr)
OA (1) OA11570A (fr)
PE (1) PE20000728A1 (fr)
PL (1) PL345024A1 (fr)
SK (1) SK19512000A3 (fr)
TR (1) TR200003888T2 (fr)
WO (1) WO2000000197A1 (fr)
ZA (1) ZA200005848B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
AU2001255620A1 (en) 2000-04-26 2001-11-07 Warner-Lambert Company Cyclohexylamine derivative as subtype selective NMDA receptor antagonists
MXPA02010863A (es) * 2000-06-01 2003-03-27 Warner Lambert Co Derivados de ciclohexilamina como subtipo de antagonistas del receptor nmda selectivo.
JP5079202B2 (ja) * 2000-07-18 2012-11-21 大日本住友製薬株式会社 セロトニン再取り込み阻害剤
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
YU64303A (sh) 2001-02-23 2006-05-25 Merck & Co.Inc. N-supstituisani nearil-heterociklični antagonisti nmda/nr2b
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
CA2381630A1 (fr) * 2001-04-23 2002-10-23 Leonard Theodore Meltzer Methode de prevention de la dyskinesie
EP1409477B1 (fr) 2001-07-24 2008-09-17 Richter Gedeon NYRT Derives de piperidine utilises en tant qu'antagonistes du recepteur n-methyl-d-aspartate (nmda)
CA2459161A1 (fr) 2001-08-31 2003-03-13 The Rockefeller University Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
EP2246053B1 (fr) * 2001-12-11 2013-09-18 University Of Virginia Patent Foundation Utilisation de pramipexole pour traiter la sclérose latérale amyotrophique
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
CA2590997A1 (fr) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
ES2334061T3 (es) * 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2679446C (fr) 2007-03-01 2016-05-17 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
RU2454409C2 (ru) 2007-03-14 2012-06-27 Нопп Ньюросайенсиз, Инк. Синтез хирально очищенных замещенных бензотиазолдиаминов
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
CN103497114A (zh) 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
TWI410420B (zh) * 2008-02-05 2013-10-01 Dainippon Sumitomo Pharma Co 苄基哌啶化合物
WO2009129497A2 (fr) * 2008-04-18 2009-10-22 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methodes et compositions de traitement de la degenerescence maculaire liee a l’age et d’identification de composes appropries
EP2334185A4 (fr) 2008-08-19 2011-09-21 Knopp Neurosciences Inc Compositions et procédés employant du (r)-pramipexole
HUP0900130A3 (en) 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
AU2010279963A1 (en) 2009-08-04 2012-02-23 Dainippon Sumitomo Pharma Co., Ltd. Benzyl piperidine compound
WO2011016861A2 (fr) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Nouvelles protéines régulatrices et nouveaux inhibiteurs
CA2772488C (fr) 2009-09-11 2018-04-17 Probiodrug Ag Derives heterocycliques en tant qu'inhibiteurs de glutaminyle cyclase
CN102883601A (zh) 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP2545047B9 (fr) 2010-03-10 2015-06-10 Probiodrug AG Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CN108042517A (zh) 2011-11-22 2018-05-18 加利福尼亚大学董事会 用于治疗缺血性损伤的半胱胺和/或胱胺
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
SI3019167T1 (sl) 2013-07-12 2021-04-30 Knopp Biosciences Llc Zdravljenje povišanih ravni eozinofilcev in / ali bazofilcev
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
PL3033081T3 (pl) 2013-08-13 2021-08-30 Knopp Biosciences Llc Kompozycje i sposoby do leczenia przewlekłej pokrzywki
WO2016100940A1 (fr) 2014-12-19 2016-06-23 The Broad Institute, Inc. Ligands des récepteurs dopaminergiques d2
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
IL272834B1 (en) 2017-08-24 2024-04-01 Adamas Pharma Llc Compositions of amantadine, their preparation, and methods of use
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase
EP3958973A4 (fr) * 2019-04-26 2023-06-07 Cytosolve, Inc. Compositions permettant d'améliorer la santé du cerveau et la mémoire

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792187A (fr) * 1971-12-03 1973-03-30 Sumitomo Chemical Co Nouveaux derives d'alkylamines
DE2845537A1 (de) * 1978-10-19 1980-04-30 Bayer Ag Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
EP0488959A3 (en) 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
JPH05194505A (ja) * 1991-08-09 1993-08-03 Yoshitomi Pharmaceut Ind Ltd チオフェン化合物
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
ATE174915T1 (de) 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
EP0825984A1 (fr) * 1995-04-07 1998-03-04 Novo Nordisk A/S Nouveau procede
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1998015550A1 (fr) * 1996-10-04 1998-04-16 Novo Nordisk A/S Composes azaheterocycliques n-substitues
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat

Also Published As

Publication number Publication date
KR20010053170A (ko) 2001-06-25
BR9911575A (pt) 2001-03-20
CN1304307A (zh) 2001-07-18
US6284774B1 (en) 2001-09-04
ATE297207T1 (de) 2005-06-15
NZ508808A (en) 2002-12-20
IS5667A (is) 2000-10-16
ZA200005848B (en) 2001-12-18
BG105082A (en) 2001-09-28
PL345024A1 (en) 2001-11-19
ID28005A (id) 2001-05-03
AP2000001949A0 (en) 2000-12-31
OA11570A (en) 2004-07-01
JP2002519322A (ja) 2002-07-02
EE200000778A (et) 2002-04-15
DE69925730D1 (de) 2005-07-14
HUP0102471A2 (hu) 2002-05-29
NO20006482D0 (no) 2000-12-19
EP1089735A1 (fr) 2001-04-11
NO20006482L (no) 2000-12-19
PE20000728A1 (es) 2000-08-21
AU769650B2 (en) 2004-01-29
DE69925730T2 (de) 2006-03-23
ES2244201T3 (es) 2005-12-01
EP1089735B1 (fr) 2005-06-08
TR200003888T2 (tr) 2001-06-21
CA2327888A1 (fr) 2000-01-06
EA200100058A1 (ru) 2001-08-27
WO2000000197A1 (fr) 2000-01-06
SK19512000A3 (sk) 2001-08-06
AU4830399A (en) 2000-01-17
EP1089735A4 (fr) 2002-12-18

Similar Documents

Publication Publication Date Title
IL138949A0 (en) 4-benzyl piperidine alkylsulfoxide heterocycles and use as subtype-selective nmda receptor antagonists
EG24533A (en) Piperdine derivatives useful as CCR 5 antagonists
EP1235798A4 (fr) Piperidinyl substitue en 1,4 efficace comme antagoniste nmda/nr2b
GB2343893B (en) Pyrrolidine derivative CCR-3 receptor antagonists
IL150033A0 (en) Selective neurokinin antagonists
GB2343894B (en) Piperidine quaternary salt CCR-3 receptor antagonists
SG80041A1 (en) Muscarinic receptor antagonists
EP1194151A4 (fr) Antagonistes des recepteurs de l'integrine
EP1229910A4 (fr) Antagonistes des recepteurs d'integrine
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
EP1061921A4 (fr) Antagonistes du recepteur de la vitronectine
EP1248607A4 (fr) Antagonistes des recepteurs de l'urotensine ii
IL181191A0 (en) Piperazine and piperidine derivatives and their use as chemokine receptor antagonists
EP1296958A4 (fr) Antagonistes des recepteurs nmda nr2b de l'iminopyrimidine
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
HK1047750A1 (zh) 趨化因子受體拮抗劑
EG24179A (en) Vitronectin receptor antagonists
IL146146A0 (en) Integrin receptor antagonists
EP1102587A4 (fr) Antagonistes du recepteur de la proteine s
GB0026327D0 (en) Thrombin receptor antagonists
HUP9901033A3 (en) 4-substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
IL120313A0 (en) Piperidine derivatives as neurokinin antagonists
GB9811283D0 (en) Vironectin receptor antagonists
GB9822701D0 (en) Intergrin receptor antagonists
AU2512800A (en) Alpha1-adrenergic receptor antagonists